Fungi play an irreplaceable role in drug discovery in the course of human history, as they possess unique abilities to synthesize diverse specialized metabolites with significant medicinal potential. Trichoderma are well-studied filamentous fungi generally observed in nature, which are widely marketed as biocontrol agents. The secondary metabolites produced by Trichoderma have gained extensive attention since they possess attractive chemical structures with remarkable biological activities. A large number of metabolites have been isolated from Trichoderma species in recent years. A previous review by Reino et al. summarized 186 compounds isolated from Trichoderma as well as their biological activities up to 2008. To update the relevant list of reviews of secondary metabolites produced from Trichoderma sp., we provide a comprehensive overview in regard to the newly described metabolites of Trichoderma from the beginning of 2009 to the end of 2020, with emphasis on their chemistry and various bioactivities. A total of 203 compounds with considerable bioactivities are included in this review, which is worth expecting for the discovery of new drug leads and agrochemicals in the foreseeable future. Moreover, new strategies for discovering secondary metabolites of Trichoderma in recent years are also discussed herein.

Marine-derived fungi are a treasure house for the discovery of structurally novel secondary metabolites with potential pharmaceutical value. In this study, a pair of new nor-bisabolane derivative enantiomers (±)−1 and two new phthalides (4 and 5), as well as four known metabolites, were isolated from the culture filtrate of the marine algal-derived endophytic fungus Penicillium chrysogenum LD-201810. Their structures were established by detailed interpretation of spectroscopic data (1D/2D NMR and ESI-MS). The optical resolution of compound (±)−1 by chiral HPLC successfully afforded individual enantiomers (+)−1 and (−)−1, and their absolute configurations were determined by TDDFT-ECD calculations. Compound (±)−1 represents the first example of bisabolane analogs with a methylsulfinyl substituent group, which is rare in natural products. All of the isolated compounds 1–7 were evaluated for their cytotoxic activity against A549, BT-549, HeLa, HepG2, MCF-7, and THP-1 cell lines, as well as for antifungal activity against four plant pathogenetic fungi (Alternaria solani, Botrytis cinerea, Fusarium oxysporum, and Valsa mali). Compound 2, a bisabolane-type sesquiterpenoid, was shown to possess excellent activity for control of B. cinerea with half-maximal inhibitory concentration (IC50) of 13.6 μg/mL, whereas the remaining investigated compounds showed either weak or no cytotoxic/antifungal activity in this study.

Cancer is the leading lethal disease worldwide. Natural products have contributed significantly to the development of approved therapeutic agents. Therefore, research into new bioactive naturally sourced metabolites with lead potential is urgently needed. It is well-known that marine microorganisms are by far one of the most notable and prolific sources of bioactive natural products. Among them, deep-sea-derived fungi are extraordinarily adapted and metabolically active under extreme environmental conditions, which enable them to produce a large number of novel secondary metabolites. Chemical examination of deep-sea-derived fungi has yielded enormous amounts of cytotoxic natural products and potential drug leads. This review summarizes a total of 229 cytotoxic compounds isolated from deep-sea-derived fungi from 2010 to 2021. The emphasis is on the unique chemical diversity of these metabolic products, together with their relevant cytotoxic properties. Among the isolated metabolites, 82 compounds have been found to possess moderate to potent cytotoxic activities. Meanwhile, we also highlight some compounds with potent cytotoxicities (namely “star molecules”) considering their high drug lead potential. This review reveals deep-sea-derived fungi as considerable resources for the development of new drugs and the potential of the newly discovered secondary metabolites as valuable antitumor lead compounds.